Lantheus Completes Acquisition of Evergreen Theragnostics. Please see the press release to learn more.


Latest Press Releases

Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

August 20, 2024

Read More at Our Investor Site

Additional Resources


Receive Email Alerts

Media Contact

Melissa Downs

Senior Director, Corporate Communications
646-975-2533

media@lantheus.com

Investors

Mark Kinarney

Vice President, Investor Relations
978-671-8842

ir@lantheus.com